<DOC>
	<DOCNO>NCT00881569</DOCNO>
	<brief_summary>This study CS-7017 design allow subject complete participation clinical study CS 7017 without experience disease progression unacceptable toxicity continue treatment study drug . Subjects progress receive CS-7017 continue benefit long administration agent .</brief_summary>
	<brief_title>Extended Use Protocol Subjects With Cancer Receive Continued Treatment With CS-7017</brief_title>
	<detailed_description>This open-label non-randomized study CS7017 design allow subject complete participation clinical study CS7017 without experience disease progression unacceptable toxicity continue treatment study drug .</detailed_description>
	<mesh_term>Efatutazone</mesh_term>
	<criteria>Subject previously treat CS7017 part study include CS7017 show clinical benefit treatment CS7017 . Anticipation need major surgical procedure radiation therapy study . Any following condition within 6 month prior initiate study treatment : Myocardial infarction significant impairment cardiac function ( eg , ejection fraction â‰¤ 50 % ) , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , NYHA class II higher congestive heart failure . Subjects clinically significant pleural pericardial effusion . Clinically significant active infection , require antibiotic therapy , HIVpositive subject receive antiretroviral therapy . Subjects diabetes mellitus require treatment insulin , sulfonylureas TZDs agent , malabsorption syndrome , chronic diarrhea , inflammatory bowel disease , partial bowel obstruction .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>